Over a decade, antipsychotic use for dementia patients nearly halved, yet dangerous polypharmacy remains stubbornly high in rural areas. This study reveals the complex trade-offs happening in Australian general practice. Dementia affects over fifty-five million people globally, with more than four hundred thirty-six thousand living with it in Australia alone.

Behavioral and psychological symptoms like agitation and aggression are major challenges that often lead to negative outcomes such as hospitalization. Psychotropic drugs are considered a second-line option after psychosocial interventions for managing these difficult behavioral symptoms.

However, evidence shows antipsychotics are effective in only about one in five people and carry risks like falls, stroke, and death. Previous studies focused on residential care, leaving a gap in understanding prescribing trends specifically for primary care patients with dementia.

This study aims to fill that gap by examining ten-year trends in psychotropic use in general practice compared to controls without dementia. This flow chart illustrates the rigorous patient selection process used to construct comparable dementia and control groups.

These steps filtered the cohorts down to a final sample of 24,701 patients with dementia and 72,105 matched controls, ensuring that subsequent analyses are based on regular practice attendees with documented diagnoses. To ensure fair comparisons, the authors matched dementia patients with controls based on sex, age, rurality, and numerous health conditions.

This rigorous matching ensures that differences in drug use reflect the impact of dementia rather than other underlying health issues. Table 1 displays the demographic and clinical characteristics of patients with dementia alongside their matched controls for the years 2011, 2014, 2017, and 2020.

By presenting these data points side-by-side, the authors demonstrate that the propensity score matching process successfully balanced key variables such as age distribution, sex, and rurality between the two groups. This baseline comparison is essential to confirm that any subsequent differences in outcomes can be attributed to the condition rather than pre-existing disparities in the study population.

In the final matched cohort, the number of patients ranged from four thousand four hundred in 2011 to nearly ten thousand in 2020. Because of the one-to-one matching strategy, the control group size exactly mirrored the dementia group size for every index year. Figure 2 tracks antipsychotic prescribing trends from 2011 to 2020, comparing patients with dementia against matched controls across different demographics.

Panel A shows that while usage rates were consistently higher in the dementia group, both cohorts experienced a significant decline over the decade. The authors further break down these trends by age, sex, and rurality in panels B through D, revealing that females generally had higher prescription rates than males within both groups.

The decline in antipsychotic prescribing was consistent across all age groups, including those eighty-five years or older. Despite the drop, prescribing rates remained highest in the oldest patients, staying above twelve percent even in 2020. Figure 3 tracks the proportion of patients prescribed psychotropic medications from 2011 to 2020, comparing those with dementia against matched controls.

The chart breaks this data down by intensity, showing trends for patients receiving at least one, two, or three different psychotropics within six months. Visually, the lines for the dementia group consistently sit higher than the control group across all categories, indicating a greater prevalence of prescribing in that population over the decade.

In 2011, forty-two percent of dementia patients had at least one psychotropic prescription, which fell to thirty-four point two percent by 2020. Meanwhile, the rate of psychotropic polypharmacy decreased from twenty-one point seven percent to eighteen point one percent in the dementia group.

Conversely, polypharmacy slightly increased in the matched control group, rising from fifteen point two percent to sixteen point six percent. The use of three or more psychotropic medications also dropped slightly in dementia patients while increasing in controls.

Figure 4 breaks down trends in psychotropic polypharmacy by sex, age, and rurality. Panel A shows that while rates declined for female dementia patients from 23.1 percent in 2011 to 18.4 percent in 2020, they slightly increased for their matched controls.

In contrast, Panel B highlights that prescribing remained stubbornly high and unchanged for the oldest cohort aged 85 years or older. Finally, Panel C reveals a geographic disparity where patients in remote areas experienced higher prevalence than those in major cities, though both groups saw a decline over the decade.

Polypharmacy was consistently higher in females with dementia, declining from twenty-three point one percent to eighteen point four percent over the study period. A large gap persisted between male dementia patients and male controls, with nineteen point three percent versus eleven point five percent in 2011.

Psychotropic polypharmacy remained stubbornly high in patients aged eighty-five or older, hovering around twenty-five percent throughout the decade. The decline in antipsychotics for this oldest group was offset by increases in opioids, antiepileptics, and antidepressants.

anchor": While antipsychotic prescribing dropped significantly, overall psychotropic polypharmacy persists in one in five dementia patients, especially among the elderly and those in remote regions.